Corbus Pharmaceuticals Holding (CRBP) Annual Income Statement (USD)
CRBP Quarterly Financials (USD)
Frequently Asked Questions About Corbus Pharmaceuticals Holding (CRBP) Stock
Corbus Pharmaceuticals Holding's (CRBP) last reported annual revenue was USD 0.00.
Corbus Pharmaceuticals Holding's (CRBP) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A
Corbus Pharmaceuticals Holding's(CRBP) is not profitable as of its last reported annual financials.
The net profit margin for Corbus Pharmaceuticals Holding's(CRBP) from its laster reported year is N/A
The return on equity (ROE) for Corbus Pharmaceuticals Holding's(CRBP) from its last reported annual financials is : -51.32%
The return on assets (ROA) for Corbus Pharmaceuticals Holding's(CRBP) from its last reported annual financials is : -28.82%
The return on invested capital (ROIC) for Corbus Pharmaceuticals Holding's(CRBP) from its last reported annual financials is : -146.77%
The Debt to Equity ratio for Corbus Pharmaceuticals Holding's(CRBP) from its last reported annual financials is : 0.00%
The dividend yield for Corbus Pharmaceuticals Holding's(CRBP) from its laster reported year is 0.00%
Corbus Pharmaceuticals Holding's(CRBP) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CRBP !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
